Hangzhou Zhongmei Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HANGZHOU ZHONGMEI
HANGZHOU ZHONGMEI has six approved drugs.
Drugs and US Patents for Hangzhou Zhongmei
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hangzhou Zhongmei | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 216493-003 | Aug 19, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hangzhou Zhongmei | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 216493-001 | Aug 19, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hangzhou Zhongmei | ACARBOSE | acarbose | TABLET;ORAL | 213821-003 | Aug 18, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hangzhou Zhongmei | TACROLIMUS | tacrolimus | CAPSULE;ORAL | 210929-002 | Apr 17, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hangzhou Zhongmei | PANTOPRAZOLE SODIUM | pantoprazole sodium | INJECTABLE;INTRAVENOUS | 209524-001 | Aug 30, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hangzhou Zhongmei | ACARBOSE | acarbose | TABLET;ORAL | 213821-001 | Aug 18, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

